Antibe Therapeutics Inc. (OTCMKTS:ATBPD – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $0.22 and last traded at $0.22, with a volume of 0 shares trading hands. The stock had previously closed at $0.22.
Antibe Therapeutics Price Performance
The company has a market cap of $83.44 million, a P/E ratio of -0.36 and a beta of 0.57. The company has a 50 day moving average of $0.45 and a 200-day moving average of $0.54.
About Antibe Therapeutics
Antibe Therapeutics Inc, a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs.
See Also
- Five stocks we like better than Antibe Therapeutics
- Learn Technical Analysis Skills to Master the Stock Market
- Silicon Motion Proves That AI in Motion Stays in Motion
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Undervalued UnitedHealth Group Won’t Be For Long
- How to Start Investing in Real Estate
- The 5 Stocks Most Sold By Insiders This Year
Receive News & Ratings for Antibe Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antibe Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
